8 results on '"He-Jun Yuan"'
Search Results
2. Pegylated Interferon and Ribavirin Promote Early Evolution of Nonstructural 5A Protein in Individuals with Hepatitis C Who Demonstrate a Response to Treatment.
- Author
-
Jain, Mamta K., He-Jun Yuan, Adams-Huet, Beverley, Reeck, Amanda, Shelton, Janel, Attar, Nahid, Song Zhang, Neumann, Avidan U., Carney, David S., Gale, Jr., Michael, and William M. Lee
- Subjects
- *
HIV-positive persons , *RIBAVIRIN , *INTERFERONS , *GENETIC polymorphisms , *HEPATITIS C virus , *ANTIVIRAL agents , *GENETIC research , *THERAPEUTICS , *LIVER diseases - Abstract
Background. Hepatitis C virus (HCV) quasispecies diversity is more likely to affect early viral decline during treatment of hepatitis C than is having human immunodeficiency virus (HIV) infection.We evaluated the influence of HCV therapy on changes in the nonstructural 5A (NS5A) protein. Methods. Fifteen patients with HCV genotype 1 infection with or without HIV infection were recruited for the present study, and the decrease in the HCV RNA level was measured at early time points. The evolution of HCV NS5A quasispecies within the first week was analyzed by comparing the clones observed at later times in the study with the baseline consensus sequence of individual patients. The response to therapy was defined as an early response (ER; ie, an HCV RNA level <615 IU/mL at week 4) or a slow response (SR; ie, a detectable HCV RNA level at week 4). Results. HIV infection did not affect early viral kinetics. At baseline, lower diversity was seen in NS5A and in the amino and carboxyl termini of patients with an ER, compared with those with an SR. Rapid evolution of the NS5A genetic region occurred in patients with an ER (P = .01) but not in those with an SR (P = .73). The evolution was the result of an increase in the number of amino acid substitutions in the carboxyl region (P = .02) in patients with an ER. Conclusions. Selective pressure appears to result in more-marked changes in individuals with an ER than in those with an SR. The carboxyl terminus was subject to the most change and may be an important determinant of phenotypic resistance to interferon-based therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
3. Nonresponse to Treatment for Hepatitis C: Current Management Strategies.
- Author
-
He-Jun Yuan and Lee, William M.
- Subjects
- *
HEPATITIS C treatment , *CIRRHOSIS of the liver , *INTERFERONS , *DRUG resistance , *IMMUNE response , *RIBAVIRIN , *THERAPEUTICS - Abstract
Chronic hepatitis C affects >170 million people worldwide, causing cirrhosis and liver cancer in a sizeable proportion of patients. Substantial progress has been made in the treatment of chronic hepatitis C. More than 50% of patients can achieve sustained virological response after 24-48 weeks of interferon and ribavirin combination therapy, making chronic hepatitis C a potentially curable disease. However, a large proportion of patients with chronic hepatitis C do not clear the virus after current standard therapy. Hepatitis C virus develops two pathways to counteract the antiviral effect of interferon. Some chronic hepatitis C patients may have a virus that is more resistant to interferon therapy, while other patients appear to have defective immune responses or poor tolerance or compliance to interferon-based antiviral therapy. The possible strategies to improve antiviral efficiency in these nonresponders are to increase the dosage, prolong the duration of treatment and improve the compliance of patients. A total of 6-15% of prior nonresponders to standard interferon plus ribavirin therapy will respond to re-treatment with peginterferon plus ribavirin, while 32-50% of patients who have relapsed will respond to re-treatment. New small molecules are under development to treat chronic hepatitis C and may be important particularly in the treatment of prior nonresponders to current standard therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
4. Significance of HBV DNA Levels in Liver Histology of HBeAg and Anti-HBe Positive Patients with Chronic Hepatitis B.
- Author
-
Man-Fung Yuen, Irene Oi-Lin Ng, Sheung-Tat Fan, He-Jun Yuan, Danny Ka-Ho Wong, John Chi-Hang Yuen, Simon Siu-Man Sum, Annie On-On Chan, and Ching-Lung Lai
- Subjects
HEPATITIS B virus ,DNA ,LIVER diseases ,HISTOLOGY ,DIAGNOSIS - Abstract
OBJECTIVE: To determine the relationship between hepatitis B virus (HBV) DNA levels and total histologic activity index (HAI), necroinflammation (HAI-NI), and fibrosis (HAI-F) scores.PATIENTS AND METHODS: Liver histology and HBV DNA levels were determined in 94 patients with chronic hepatitis B.RESULTS: There was no association between HBV DNA levels and liver histology in hepatitis-B-e antigen-positive patients (n= 43). In anti-HBe-positive patients (n= 51), HBV DNA levels correlated positively with HAI-NI (r= 0.31,p= 0.014) and HAI-F (r= 0.33,p= 0.017) scores. Though the majority of anti-HBe-positive patients with HBV DNA levels<10
5 copies/ml had mild necroinflammation and no fibrosis, 14.3% had established fibrosis. Anti-HBe-positive patients with core promoter mutations had a poorer histology compared to those without. There was no difference in the histology between anti-HBe-positive patients with and without precore mutations. Alanine aminotransferase (ALT) level correlated positively with HAI-NI score. Patients with persistently normal ALT levels had a significantly lower median HAI-NI score compared to patients with either persistently or intermittently elevated ALT levels.CONCLUSIONS: In anti-HBe-positive patients, though HBV DNA level<105 copies/ml was associated with better histology, 14.3% patients had established fibrosis. Further studies to define a better cut-off HBV DNA level to differentiate low- and high-risk patients for disease progression are required. [ABSTRACT FROM AUTHOR]- Published
- 2004
- Full Text
- View/download PDF
5. Role of Hepatitis B Virus Genotypes in Chronic Hepatitis B Exacerbation.
- Author
-
Man-Fung Yuen, Sablon, Erwin, Ka-Ho Wong, Danny, He-Jun Yuan, Chun-Yu Wong, Benjamin, On-On Chan, Annie, and Ching-Lung Lai
- Subjects
HEPATITIS B virus ,BILIRUBIN ,ALBUMINS - Abstract
Hepatitis B virus (HBV) genotypes and precore and core promoter mutations were determined in 318 patients with HBV. Patients infected with HBV genotype B had a higher median alanine aminotransferase level and bilirubin level and a lower median albumin level during exacerbations of disease, compared with patients infected with HBV genotype C (all P < .001). By logistic regression analysis, HBV genotype B infection (P = .014) and low albumin levels (P = .006) were independently associated with a higher risk of hepatic decompensation during severe exacerbations of disease. Patients infected with genotype B had a significantly higher mortality due to hepatic decompensation than did patients with genotype C (70% vs. 27.8%; P = .05). [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
6. Prognostic Factors in Severe Exacerbation of Chronic Hepatitis B.
- Author
-
Man-Fung Yuen, Sablon, Erwin, Chee-Kin Hui, Tak-Ming Li, He-Jun Yuan, Ka-Ho Wong, Danny, Doutreloigne, Joke, Bogaerts, Veerle, Chun-Yu Wong, Benjamin, Sheung-Tat Fan, and Ching-Lung Lai
- Subjects
HEPATITIS B ,LIVER transplantation ,PROGNOSIS - Abstract
Identifies prognostic factors for patients with severe exacerbation of chronic hepatitis B infection and examines the role of precore and core promoter mutations in such exacerbations. Need for patients with severe exacerbation of hepatitis B with poor prognostic factors to be considered for liver transplantation.
- Published
- 2003
- Full Text
- View/download PDF
7. Relationship between the Development of Precore and Core Promoter Mutations and Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B Virus.
- Author
-
Man-Fung Yuen, Sablon, Erwin, He-Jun Yuan, Chee-Kin Hui, Wong, Danny Ka-Ho, Doutreloigne, Joke, Wong, Benjamin Chun-Yu, Chan, Annie On-On, and Ching-Lung Lai
- Subjects
HEPATITIS B virus ,GENETIC mutation - Abstract
Chinese patients with chronic hepatitis B virus (332 with and 44 without cirrhosis-related complications) were studied. Fifty percent of patients <30 years old had precore mutations. The prevalence of precore mutations among hepatitis B e antigen (HBeAg)-positive patients, although lower than that among anti-HBe-positive patients (P = .031), was already high (44.2%). Median HBV DNA level in anti-HBe-positive patients was 1.5 x 10[SUP6]-1.55 x 10[SUP6] copies/mL, irrespective of the presence or absence of precore mutations. There was no difference in the prevalence of precore mutations between patients with and without complications (P, not significant). However the prevalence of core promoter mutations was higher among patients with complications than among those without complications (90.5% vs. 69.3%, respectively; P = .003). In conclusion, precore mutations occurred in a large proportion of Chinese patients with chronic hepatitis B virus before HBeAg seroconversion. The development of complications was not related to precore mutations but was probably due to the persistence of significant viremia after HBeAg seroconversion. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
8. Analysis of serum α-fetoprotein concentration in patients with viral hepatitis.
- Author
-
Wei Min She, De Chang Hu, He Jun Yuan, Wei Rong Zhai, Yi Liang, and Hou Yu Liu
- Subjects
- *
ALPHA fetoproteins , *VIRAL hepatitis , *SERUM - Abstract
OBJECTIVE: To investigate serum α-fetoprotein (AFP) concentrations in patients with viral hepatitis. METHODS: Serum concentrations of total bilirubin (TB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, globulin, AFP and viral markers were determined in 310 patients with pathologically proven viral hepatitis. The relation between the concentration of AFP and clinical manifestation, pathology, family history of liver malignant disease and virus type was studied. RESULTS: Serum AFP concentrations were elevated in 115 of the 310 patients (37.1%). According to the pathological diagnosis, the lowest positive rate of AFP was in acute hepatitis (11.7%), the highest was in chronic severe hepatitis (66.7%), the second highest in liver cirrhosis (57.5%), and chronic hepatitis was intermediate (34.2%). If the diagnosis was based on the clinical manifestation, the highest positive rate was found in chronic severe hepatitis, the lowest in chronic hepatitis, and acute hepatitis was intermediate. The positive rate of serum AFP by virus type was 35.5% for hepatitis B (HBV), superinfected with HAV or with HEV was 62.8%, and with HCV was 27.3%. Only one in six patients with HCV infection and none with simple HAV or HEV infection were positive for AFP. In patients with a family history of liver cancer, the positive rate of AFP was higher than in those without such a history (57.9%vs 38.2%; P = 0.75). CONCLUSIONS: The results indicate that AFP positivity is not uncommon in patients with viral hepatitis and if the patient has an elevated concentration, it is highly likely to be HBV infection or HBV superinfected with HAV or HEV. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.